Clinical Trial: A prospective, multicenter study to evaluate the efficacy and safety of adding obinutuzumab (O-triple) to standard therapy consisting of mycophenolate mofetil (MMF) and glucocorticoids as an initial treatment regimen for patients with active lupus nephritis. (China)

China, Aug. 24 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'A prospective, multicenter study to evaluate the efficacy and safety of adding obinutuzumab (O-triple) to standard therapy consisting of mycophenolate mofetil (MMF) and glucocorticoids as an initial treatment regimen for patients with active lupus nephritis.'. The following are the other relevant details related to the trial:

Registration Number: ChiCTR2600130589

Registration Time: 2026/08/21

Type: Interventional study

Primary Sponsor: Peking University First Hospital

To know more, click on https://www.chictr.org.cn/showprojEN.html?proj=328666

Published by HT Digital Content Services with permission from Health Daily Digest...